Outsourcing

Feliza Mirasol is the science editor for 

Articles

Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.

Insights into Outsourced vs. In-house Clinical Trial Services

Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.

Moderna and Thermo Fisher Scientific Form Long-Term Strategic Manufacturing Collaboration

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

Thermo Fisher Scientific Invests $40 Million to Expand Bioprocessing Manufacturing Site

Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.

Piramal Pharma Solutions Expands and Upgrades UK Manufacturing Facilities

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Cytiva Provides Arranta Bio with Single-Use Manufacturing Platform for mRNA Products

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

James Park is executive vice-president and managing director of the Global Sales Center at Samsung Biologics.

CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.

Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal 

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities. 

Contract Manufacturing, Biopharmaceutical Production